To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile BRAF V600E
Therapy Dabrafenib + Trametinib
Indication/Tumor Type papillary craniopharyngioma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600E papillary craniopharyngioma predicted - sensitive Dabrafenib + Trametinib Case Reports/Case Series Actionable In a clinical case study, treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a 95% decrease in tumor size in a patient with papillary craniopharyngioma harboring BRAF V600E (PMID: 35023192). 35023192
BRAF V600E papillary craniopharyngioma predicted - sensitive Dabrafenib + Trametinib Case Reports/Case Series Actionable In a clinical case study, neoadjuvant treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in sustained radiologic response after 3 months of treatment followed by a tumor-free period lasting 2 years from treatment discontinuation in a patient with papillary craniopharyngioma harboring BRAF V600E (PMID: 37683921). 37683921
BRAF V600E papillary craniopharyngioma predicted - sensitive Dabrafenib + Trametinib Case Reports/Case Series Actionable In a clinical case study, treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in decreased tumor size and symptom improvement in a patient with recurrent papillary craniopharyngioma harboring BRAF V600E, with treatment ongoing for at least 7 months (PMID: 28425764). 28425764
BRAF V600E papillary craniopharyngioma predicted - sensitive Dabrafenib + Trametinib Case Reports/Case Series Actionable In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a 70% cyst volume reduction and 52% decreased enhancing volume followed by combination treatment with Mekinist (trametinib) resulting in 81% cyst volume reduction and 85% enhancing volume reduction in a patient with recurrent papillary craniopharyngioma harboring BRAF V600E (PMID: 26498373). 26498373
PubMed Id Reference Title Details
(28425764) BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. Full reference...
(37683921) Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma. Full reference...
(35023192) Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift. Full reference...
(26498373) Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Full reference...